1,400 Girls Not Born in Armenia Annually Because of Sex-Selective Abortions - Report
By News.am,
News.am
| 06. 15. 2012
YEREVAN.- The report issued by the United Nations Population Fund (UNFPA) says 1,400 girls are not born in Armenia every year because of sex-selective abortions.
The report was prepared by UNFPA with the assistance of Armenia’s Health Ministry and the Institute of Reproductive Health, Perinatology, Obstetrics and Gynecology.
According to official statistics, since 1993 the ratio newborns makes 110-120 boys per 100 girls which is significantly higher as compared to the average that is seen as a biological norm (102-106).
Sociologist Artak Saghatelyan the reason for such figures is sex selective abortion. The study was conducted in 2011 in 2830 households, among ever-pregnant women aged 15 -49.
According to Saghatelyan, the study suggests that within the last 5 years 0.8% of 2,925 women of reproductive age (15-49 year-olds) in 2,830 households covered by the survey had a sex-selective abortion.
Abortion is most often carried out during the third and fourth pregnancies often by women living in urban areas as well as women with higher education and high income (100,000 AMD and more).
However, 44% of respondents stated they do not...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...